Atea Pharmaceuticals (AVIR) Scheduled to Post Quarterly Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to be announcing its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Tuesday, May 14th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.14). On average, analysts expect Atea Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Performance

Shares of AVIR stock opened at $3.82 on Thursday. The company has a market capitalization of $321.72 million, a P/E ratio of -1.95 and a beta of 0.18. The company’s 50 day moving average price is $3.60 and its two-hundred day moving average price is $3.81. Atea Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $4.60.

Insiders Place Their Bets

In other news, Director Bruce Polsky sold 17,544 shares of Atea Pharmaceuticals stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $3.49, for a total value of $61,228.56. Following the sale, the director now directly owns 65,606 shares in the company, valued at $228,964.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 17.80% of the company’s stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.